[Results of a study of the resorption of bufexamac following rectal administration].
12 patients suffering from hemorrhoidal complaints were treated with hemorrhoidal suppositories containing Proctoparf-bufexamac. Using the HPCL method, we measured the concentrations of bufexamac in the serum after 30, 45 and 60 minutes as well as after 2, 3, 6, 7.5 and 20 hours. Neither bufexamac nor its major metabolite (4-butoxyphenyl acetic acid) could be detected in concentrations above 0.2 micrograms/ml and 0.5 micrograms/ml, respectively. These results prove that the application of Proctoparf suppositories is not associated with any significant systemic absorption of bufexamac.
Glowania
H J
HJ
Bundeswehrzentralkrankenhaus Koblenz, Dermatol.-Venerol, Abteilung.
Hampl
B
B
D002019:Bufexamac / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006484:Hemorrhoids / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D006877:Hydroxamic Acids / Q000493:pharmacokinetics*; D013488:Suppositories
D006877:Hydroxamic Acids; D013488:Suppositories; D002019:Bufexamac
Ergebnisse einer Untersuchung über die Resorption von Bufexamac nach rektaler Anwendung.